Ra Pharmaceuticals, Inc.
(NASDAQ : RARX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 1.14%33.840.9%$1138.25m
JNJJohnson & Johnson 0.01%142.500.7%$1016.34m
BMYBristol-Myers Squibb Co. -1.17%57.431.0%$922.01m
MRKMerck & Co., Inc. 0.05%76.730.7%$787.68m
ABBVAbbVie, Inc. -1.18%96.781.9%$725.30m
LLYEli Lilly & Co. -1.84%163.391.1%$641.93m
AZNAstraZeneca Plc -0.40%53.761.2%$288.49m
RPRXRoyalty Pharma Plc -1.49%47.640.1%$203.76m
NVSNovartis AG -0.36%87.030.2%$143.34m
RGENRepligen Corp. -1.97%126.137.1%$115.34m
GSKGlaxoSmithKline Plc -1.14%39.910.2%$109.88m
NVONovo Nordisk A/S -0.26%65.440.1%$88.47m
RETAReata Pharmaceuticals, Inc. -1.10%154.403.4%$79.42m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -2.31%74.140.0%$67.56m
SNYSanofi -0.53%50.280.2%$63.74m

Company Profile

Ra Pharma is developing Cyclomimetics, a new drug class with the diversity and specificity of antibodies, coupled with the many benefits of small molecules. Ra Pharma’s peptide-like molecules are highly-stable, synthetic products with chemical structures that offer intrinsic cell permeability. Ra Pharma is leveraging its ability to rapidly generate drug candidates to develop its own portfolio of products and partnerships focused on intracellular protein-protein interactions and other innovative approaches to addressing unmet medical needs.